TY - JOUR
T1 - Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients
T2 - A multicenter cohort study
AU - Manuel, Oriol
AU - Husain, Shahid
AU - Kumar, Deepali
AU - Zayas, Carlos
AU - Mawhorter, Steve
AU - Levi, Marilyn E.
AU - Kalpoe, Jayant
AU - Lisboa, Luiz
AU - Ely, Leticia
AU - Kaul, Daniel R.
AU - Schwartz, Brian S.
AU - Morris, Michele I.
AU - Ison, Michael G.
AU - Yen-Lieberman, Belinda
AU - Sebastian, Anthony
AU - Assi, Maha
AU - Humar, Atul
N1 - Funding Information:
Financial support. This work was supported by the Alberta Transplant Institute Innovation Fund and by an unrestricted grant from Roche Pharmaceuticals Switzerland.
PY - 2013/3/15
Y1 - 2013/3/15
N2 - Background. Cytomegalovirus (CMV) disease remains an important problem in solid-organ transplant recipients, with the greatest risk among donor CMV-seropositive, recipient-seronegative (D+/R-) patients. CMV-specific cell-mediated immunity may be able to predict which patients will develop CMV disease. Methods. We prospectively included D+/R - patients who received antiviral prophylaxis. We used the Quantiferon-CMV assay to measure interferon- levels following in vitro stimulation with CMV antigens. The test was performed at the end of prophylaxis and 1 and 2 months later. The primary outcome was the incidence of CMV disease at 12 months after transplant. We calculated positive and negative predictive values of the assay for protection from CMV disease. Results. Overall, 28 of 127 (22%) patients developed CMV disease. Of 124 evaluable patients, 31 (25%) had a positive result, 81 (65.3%) had a negative result, and 12 (9.7%) had an indeterminate result (negative mitogen and CMV antigen) with the Quantiferon-CMV assay. At 12 months, patients with a positive result had a subsequent lower incidence of CMV disease than patients with a negative and an indeterminate result (6.4% vs 22.2% vs 58.3%, respectively; P <. 001). Positive and negative predictive values of the assay for protection from CMV disease were 0.90 (95% confidence interval [CI],. 74-.98) and 0.27 (95% CI,. 18-.37), respectively. Conclusions. This assay may be useful to predict if patients are at low, intermediate, or high risk for the development of subsequent CMV disease after prophylaxis.
AB - Background. Cytomegalovirus (CMV) disease remains an important problem in solid-organ transplant recipients, with the greatest risk among donor CMV-seropositive, recipient-seronegative (D+/R-) patients. CMV-specific cell-mediated immunity may be able to predict which patients will develop CMV disease. Methods. We prospectively included D+/R - patients who received antiviral prophylaxis. We used the Quantiferon-CMV assay to measure interferon- levels following in vitro stimulation with CMV antigens. The test was performed at the end of prophylaxis and 1 and 2 months later. The primary outcome was the incidence of CMV disease at 12 months after transplant. We calculated positive and negative predictive values of the assay for protection from CMV disease. Results. Overall, 28 of 127 (22%) patients developed CMV disease. Of 124 evaluable patients, 31 (25%) had a positive result, 81 (65.3%) had a negative result, and 12 (9.7%) had an indeterminate result (negative mitogen and CMV antigen) with the Quantiferon-CMV assay. At 12 months, patients with a positive result had a subsequent lower incidence of CMV disease than patients with a negative and an indeterminate result (6.4% vs 22.2% vs 58.3%, respectively; P <. 001). Positive and negative predictive values of the assay for protection from CMV disease were 0.90 (95% confidence interval [CI],. 74-.98) and 0.27 (95% CI,. 18-.37), respectively. Conclusions. This assay may be useful to predict if patients are at low, intermediate, or high risk for the development of subsequent CMV disease after prophylaxis.
KW - Quantiferon-CMV
KW - antiviral prophylaxis
KW - late-onset CMV disease
KW - protection
UR - http://www.scopus.com/inward/record.url?scp=84874774789&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84874774789&partnerID=8YFLogxK
U2 - 10.1093/cid/cis993
DO - 10.1093/cid/cis993
M3 - Article
C2 - 23196955
AN - SCOPUS:84874774789
SN - 1058-4838
VL - 56
SP - 817
EP - 824
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 6
ER -